Clinical trials: Seborrheic Dermatitis
Hirsutism, Androgenetic Alopecia
DUS on the Prescribing Indications for CPA/EE in 5 European Countries
This study was designed to compile the reasons and specific indications for the prescription of Cyproterone Acetate combined with Ethinyl Estradiol by Health Care Providers.
- Conditions
- Hirsutism, Androgenetic Alopecia, Severe Anemia, Seborrhea
- Trial name
- NCT02494297
- Where
- Germany
- Volunteers
- 1,597 people, healthy volunteers welcome
- Sponsor
- Center for Epidemiology and Health Research, Germany
Cradle Cap, Seborrheic Dermatitis
TRIDERM D.S. Crema Normalizzante for Neonatal Hyperseborrhea (Cradle Cap) and Associated Cutaneous Manifestations of Mild-to-Moderate Seborrheic Dermatitis in Children Aged 0 to 3 Years
This clinical study aims to evaluate the effects of using the cosmetic product TRIDERM D.S. Crema Normalizzante in children aged 0 to 3 years with neonatal hyperseborrhea ("cradle cap"), potentially associated with manifestations…
- Trial name
- NCT07860788
- Testing
- TRIDERM D.S. Crema Normalizzante
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- ICIM International S.r.l.
Seborrheic Dermatitis
Efficacy and Safety of Roflumilast Foam 0.3% in Trial Participants With Seborrheic Dermatitis
This study will assess the safety and efficacy of Roflumilast foam 0.3% (ZORYVE®) versus vehicle applied once a day for 8 weeks by trial participants with seborrheic dermatitis.
- Trial name
- NCT07683806
- Testing
- Roflumilast Foam 0.3%, Vehicle foam
- Where
- 52 sites in China
- Volunteers
- 309 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Dermatitis, Seborrheic, Dry Skin; Eczema
Safety and Efficacy of a Topical Scalp Treatment for Dry Scalp Conditions in Children and Adult
The purpose of this study is to evaluate the safety and efficacy of a novel topical treatment for dry scalp conditions, including dandruff, seborrheic dermatitis, and atopic dermatitis.
- Trial name
- NCT03830177
- Testing
- Natural Treatment
- Where
- United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
Seborrheic Dermatitis
Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)
This phase 3, double-blind, vehicle-controlled study assessed the safety and efficacy of roflumilast (ARQ-154) foam 0.3% applied once daily (qd) for 8 weeks by participants with seborrheic dermatitis.
- Trial name
- NCT04973228
- Testing
- Roflumilast Foam, Vehicle Foam
- Where
- 53 sites in United States, Canada
- Volunteers
- 457 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Signs of Androgenisation in Women, e.g. Hirsutism, Androgenetic Alopecia, Acne and Seborrhea, Hypersexuality in Men
A Study to Learn About the Awareness and Knowledge That Doctors Have About the Safety and Safe Use Information for Androcur and Other Cyproterone Acetate Treatments in Europe
Androcur is a type of treatment called cyproterone acetate (CPA). Androcur and other CPA treatments work by blocking a group of male sex hormones called androgens in the body.
- Conditions
- Signs of Androgenisation in Women, e.g. Hirsutism, Androgenetic Alopecia, Acne and Seborrhea, Hypersexuality in Men, Sexual Deviations in Men, Prostate Cancer
- Trial name
- Safe-CAM (NCT04925180)
- Testing
- Cyproterone Acetate (Androcur, BAY94-8367)
- Where
- 5 sites in France, Germany and 3 more
- Volunteers
- 600 people
- Sponsor
- Bayer
Seborrheic Dermatitis
Safety and Efficacy Study in Subjects With Seborrheic Dermatitis
The purpose of this study is to determine if two test products are safe and effective in the treatment of seborrheic dermatitis.
- Trial name
- NCT01703793
- Testing
- Test Product 49778, Test Product 10156
- Where
- 22 sites in United States
- Volunteers
- 240 people
- Sponsor
- Medicis Global Service Corporation
Cradle Cap, Infantile Seborrheic Dermatitis
Promiseb Topical Cream for Cradle Cap
The purpose of this study is to evaluate the efficacy and safety of Promiseb Topical Cream in cradle cap.
- Trial name
- NCT01214434
- Testing
- Promiseb Topical Cream, Bland emollient
- Where
- 4 sites in United States
- Volunteers
- 42 people
- Sponsor
- Promius Pharma, LLC
Seborrheic Dermatitis, Psoriasis of Scalp
Study to Evaluate the Safety of Sebryl® and Sebryl Plus® in Seborrheic Dermatitis and Psoriasis of Scalp
Observational, descriptive, retrospective, multicenter study to evaluate the safety of the treatment with Sebryl® and / or Sebryl Plus® in the management of seborrheic dermatitis and psoriasis of the scalp in routine medical…
- Trial name
- NCT05105139
- Testing
- Allantoin/ Coal Tar/ Clioquinol, Allantoin/ Coal Tar/ Clioquinol/ Triclosan
- Where
- Mexico
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Laboratorios Silanes S.A. de C.V.
Seborrheic Dermatitis
Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis
This is an open-label, long-term safety study of roflumilast ARQ-154 foam 0.3% in subjects with seborrheic dermatitis involving up to 20% total Body Surface Area (BSA). Study was applied topically once daily for 52 weeks.
- Trial name
- NCT04445987
- Testing
- ARQ-154
- Where
- 39 sites in United States
- Volunteers
- 408 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
HIV, AIDS
HIV Indicator Diseases Survey Across Europe - UK Arm
In Europe many patients infected with HIV remain undiagnosed, although this percentage varies between 15-80% across the continent. In the UK it is estimated to be 27%.
- Conditions
- HIV, AIDS, Indicator Diseases/Indicator Conditions
- Trial name
- NCT01196468
- Testing
- HIV test (serological or salivary), Interview
- Where
- 2 sites in United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- Chelsea and Westminster NHS Foundation Trust
Dermatitis, Seborrheic
STUDY TO ASSESS THE LONG-TERM SAFETY OF EXTINA (KETOCONAZOLE) FOAM, 2%
Extina (ketoconazole) Foam, 2% was approved for marketing in the United States (US) in June 2007. Extina foam is indicated for topical treatment of seborrheic dermatitis in immunocompetent patients 12 years of age and older.
- Trial name
- NCT00703846
- Testing
- Ketoconazole
- Volunteers
- 498 people
- Sponsor
- Stiefel, a GSK Company
Dermatitis, Atopic, Dermatitis, Contact
Efficacy and Tolerability of Prednisolone Acetate 0.5% Cream Versus Betamethasone Valerate 0.1% Cream in Cortisosensitive Dermatosis
Topical corticosteroids are largely used in dermatology. The major problem related to their use is that the same mechanisms underlying their therapeutic effects (antiinflammatory and antiproliferative) may lead to adverse events.
- Conditions
- Dermatitis, Atopic, Dermatitis, Contact, Dermatitis, Seborrheic, Psoriasis
- Trial name
- NCT01011621
- Testing
- 0.5% prednisolone acetate cream, 0.1% betamethasone valerate cream
- Volunteers
- 170 people
- Sponsor
- Mantecorp Industria Quimica e Farmaceutica Ltd.